Therapeutics

Displaying 1 - 10 of 24

Anti-inflammatory microparticles for sustained ocular drug delivery

Vanderbilt researchers have developed an injectable drug delivery vehicle using microparticles (MPs) that not only provide sustained cargo delivery over extended time but also play a therapeutic role themselves in reducing inflammation. This drug delivery platform can be used in treating ocular diseases such as glaucoma and traumatic optic neuropathy, as well as other inflammatory diseases throughout the body like peripheral arterial disease and osteoarthritis.

Licensing Contact

Taylor Jordan

615.936.7505

Inventors

Craig Duvall, Carlisle DeJulius, Richard d'Arcy, Tonia Rex, Sarah Naguib
Category:
Therapeutics
Field of Use:
Inflammatory/Immune/Wound Repair Opthamology

Targeted photodynamic therapy for S. aureus infections

Vanderbilt researchers have developed a combination photodynamic therapy (PDT) for targeting MRSA infections in skin that is not only effective but also HIGHLY SPECIFIC and LESS SUSCEPTIBLE TO RESISTANCE, adding a much needed therapy to our quickly depleting arsenal against this pathogen.

Licensing Contact

Cameron Sargent

615.322.5907

Inventors

James Crowe, Eric Skaar, Matthew Surdel, Gary A Sulikowski, Paul Reid, Brendan Dutter, Alex Waterson
Category:
Therapeutics
Field of Use:
Dermatology Dermatology Infectious Disease Infectious Disease Infectious Disease
Modality:
Antibody Small Molecule

Targeting PD-1H to treat Acute Myeloid Leukemia (AML)

Despite the success of immune checkpoint inhibitors (ICI) like anti-PD-1 in treating other cancers, these therapeutics have not been demonstrated to effectively treat acute myeloid leukemia (AML). Vanderbilt researchers have identified PD-1H as a potential target for treating AML, opening the door for effective therapy using an ICI molecule.

Licensing Contact

Cameron Sargent

615.322.5907

Inventors

Tae Kon Kim
Category:
Therapeutics
Field of Use:
Oncology

Targeted light-based therapy for acne

Vanderbilt researchers have developed a photodynamic therapy (PDT) for effectively and specifically treating acne, the most common skin condition.

Licensing Contact

Cameron Sargent

615.322.5907

Inventors

Eric Skaar, Matthew Surdel, Gary A Sulikowski, Paul Reid, Brendan Dutter, Alex Waterson
Category:
Therapeutics
Field of Use:
Dermatology Infectious Disease
Modality:
Small Molecule

Fused in Sarcoma (FUS) Nuclear Translocation Inhibitors for Preventing Fibrosis

The research team has found that one of the key regulators of collagen production in fibrotic diseases is the FUS ribonucleoprotein. This protein is upregulated in fibrotic diseases leading to additional collagen formation and deposition. In order to combat FUS upregulation, a new approach to blocking nuclear translocation has been developed using an FUS targeting peptide approach.

Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Jack Hawiger, Manuel Chiusa, Ambra Pozzi, Jozef Zienkiewicz
Category:
Therapeutics

Systems and Methods for Optical Stimulation of Neural Tissues (Portfolio)

Vanderbilt researchers have developed a novel technique for contactless simulation of the central nervous system.  This involves the use of infrared neural stimulation (INS) to evoke the observable action potentials from neurons of the central nervous system.  While infrared neural stimulation of the peripheral nervous system was accomplished almost a decade ago, this is the first technique for infrared stimulation of the central nervous system. This technology has been protected by a portfolio of issued patents.

Licensing Contact

Masood Machingal

615.343.3548

Inventors

Eric Jansen, Anita Mahadevan-Jansen, Jonathan Cayce, Austin Duke, Peter Konrad, Jay Walsh, Robert Friedman, Agnelia Izzo, Karthikeyan Mariappan, Jonathon Wells, Claus-Peter Richter, Anna Roe, Changqing Kao, Mykyta Chernov, Charles Lemaire, James Webb, Mark Bendett
Category:
Diagnostics Medical Devices Medical Imaging Therapeutics

Oral administration of levocarnitine for treating Sjögren's Syndrome-associated dry eye

Sjögren's syndrome (SjS) is a common and debilitating autoimmune disease, causing dry eye symptoms ranging from discomfort to dysfunction. Vanderbilt researchers have identified orally administered levocarnitine as a novel potential therapeutic for treating this condition.

Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Jill Pulley, Jillian Rhoads, Leslie Crofford
Category:
Natural Products Therapeutics
Field of Use:
Opthamology

mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).

Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Craig Lindsley, P. Jeffrey Conn, Kyle Emmitte, Julie Engers, Leah Konkol
Category:
Therapeutics
Field of Use:
Neuroscience/Neurology Oncology
Modality:
Small Molecule

Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.

Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Craig Lindsley, P. Jeffrey Conn, Kyle Emmitte, Julie Engers, Leah Konkol
Category:
Therapeutics
Field of Use:
Neuroscience/Neurology Oncology
Modality:
Small Molecule

Small Molecule-GIRK Potassium Channel Modulators That Are Anxiolytic Therapeutics

The G-protein activated, inward-rectifying potassium (K+) channels, "GIRKs", are a family of ion channels that has been the focus of intense research interest for nearly two decades. GIRK has been shown to play important roles in the pathophysiology of diseases such as anxiety, epilepsy, Down's syndrome, pain perception and drug addiction. Here scientists at Vanderbilt developed the first truly potent, effective, and selective GIRK activator, ML297 (VU0456810) and demonstrated that ML297 is active in animal models of epilepsy. While the group is using ML297 to continue to explore the therapeutic benefits of GIRK modulation, they are continuing to develop more selective and druggable GIRK inhibitors from different scaffolds.

Licensing Contact

Cameron Sargent

615.322.5907

Inventors

Charles Weaver, P. Jeffrey Conn
Category:
Therapeutics
Field of Use:
Analgesic
Modality:
Small Molecule